Clinical Trial Update: The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomicronemia Syndrome [Phase 3]

View source ↗

Summary

Phase 3 open-label study of volanesorsen in familial chylomicronemia syndrome has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Chylomicronemia Syndrome
• Hyperlipoproteinemia Type 1
• Lipoprotein Lipase Deficiency

Drugs mentioned

• Volanesorsen (volanesorsen)

Snippet

Sponsor: Akcea Therapeutics | Conditions: Familial Chylomicronemia Syndrome, Lipoprotein Lipase Deficiency | Phase 3 | Status: COMPLETED | Results posted: 2021-08-26